GL
Gary K. Lee
Chief Scientific Officer

Gary K. Lee insider trades: Lyell Immunopharma (LYEL) stock sales

Chief Scientific Officer, Lyell Immunopharma Last trade Aug 21, 2026 14 Form 4 filings
$72K
Sold, last 12 months
6 sales
$0
Bought, last 12 months
0 buys
8
Open-market trades
since 2025
1
Company
last trade 2026

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Gary reports to the SEC

Open-market buys and sales

8 trades reported on SEC Form 4, newest first

DateStockTypeValue
Aug 21, 2026LYEL↓ Sell$23K
Aug 10, 2026LYEL↓ Sell$2K
May 11, 2026LYEL↓ Sell$2K
Feb 11, 2026LYEL↓ Sell$39K
Feb 10, 2026LYEL↓ Sell$3K
Nov 10, 2025LYEL↓ Sell$2K
Aug 21, 2025LYEL↓ Sell$15K
Aug 12, 2025LYEL↓ Sell$3K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other LYEL insiders

Open-market trades in the last 12 months

About Gary K. Lee's insider trades

Gary K. Lee is Chief Scientific Officer at Lyell Immunopharma (LYEL). Since Aug 12, 2025, Gary has reported no open-market purchases and 8 sales worth $90K on SEC Form 4. In the last 12 months: 6 sales ($72K).

Their filings also include grants and awards (8 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every LYEL insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.